Cargando…

Effect of Teduglutide, a Glucagon-like Peptide 2 Analog, on Citrulline Levels in Patients With Short Bowel Syndrome in Two Phase III Randomized Trials

OBJECTIVES: In clinical trials, treatment with the glucagon-like peptide 2 analog teduglutide was associated with improved fluid and nutrient absorption and increased intestinal villus height and crypt depth in patients with short bowel syndrome (SBS). Plasma citrulline, an amino acid produced by en...

Descripción completa

Detalles Bibliográficos
Autores principales:	Seidner, Douglas L, Joly, Francisca, Youssef, Nader N
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2015
Materias:	Original Contributions
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4816243/ https://www.ncbi.nlm.nih.gov/pubmed/26111125 http://dx.doi.org/10.1038/ctg.2015.15

Ejemplares similares

Long-Term Teduglutide for the Treatment of Patients With Intestinal Failure Associated With Short Bowel Syndrome
por: Schwartz, Lauren K, et al.
Publicado: (2016)

Teduglutide for short bowel syndrome
Publicado: (2020)

Enteral Autonomy and Days Off Parenteral Support With Teduglutide Treatment for Short Bowel Syndrome in the STEPS Trials
por: Seidner, Douglas L., et al.
Publicado: (2019)

Teduglutide for the treatment of adults with intestinal failure associated with short bowel syndrome: pooled safety data from four clinical trials
por: Pape, Ulrich-Frank, et al.
Publicado: (2020)

Patients With Short Bowel on Narcotics During 2 Randomized Trials Have Abdominal Complaints Independent of Teduglutide
por: Fujioka, Ken, et al.
Publicado: (2016)

Independence From Parenteral Nutrition and Intravenous Fluid Support During Treatment With Teduglutide Among Patients With Intestinal Failure Associated With Short Bowel Syndrome
por: Iyer, Kishore R., et al.
Publicado: (2016)

Post-Marketing Use of Teduglutide in a Large Cohort of Adults with Short Bowel Syndrome-Associated Chronic Intestinal Failure: Evolution and Outcomes
por: de Dreuille, Brune, et al.
Publicado: (2023)

Emerging treatment options for short bowel syndrome: potential role of teduglutide
por: Tee, Cheng T, et al.
Publicado: (2011)

Targeted therapy of short-bowel syndrome with teduglutide: the new kid on the block
por: Vipperla, Kishore, et al.
Publicado: (2014)

Short Bowel Syndrome and Kidney Transplantation: Challenges, Outcomes, and the Use of Teduglutide
por: Abou Diwan, Elizabeth, et al.
Publicado: (2020)

Safety and Efficacy of Teduglutide in Pediatric Patients With Intestinal Failure due to Short Bowel Syndrome: A 24‐Week, Phase III Study
por: Kocoshis, Samuel A., et al.
Publicado: (2019)

Efficacy, safety, and pharmacokinetics of teduglutide in adult Japanese patients with short bowel syndrome and intestinal failure: two phase III studies with an extension
por: Nakamura, Shiro, et al.
Publicado: (2022)

Teduglutide in short bowel syndrome patients: A way back to normal life?
por: Harpain, Felix, et al.
Publicado: (2021)

Impact of Teduglutide on Quality of Life Among Patients With Short Bowel Syndrome and Intestinal Failure
por: Chen, Kristina, et al.
Publicado: (2019)

Effects of Teduglutide on Diarrhea in Pediatric Patients with Short Bowel Syndrome-Associated Intestinal Failure
por: Fifi, Amanda, et al.
Publicado: (2023)

Efficacy and Safety of Teduglutide in Infants and Children With Short Bowel Syndrome Dependent on Parenteral Support
por: Chiba, Masahiro, et al.
Publicado: (2023)

An updated overview of glucagon-like peptide-2 analog trophic therapy for short bowel syndrome in adults
por: Zhu, Changzhen, et al.
Publicado: (2022)

Population pharmacokinetics and exposure‐response analyses of teduglutide in adult and pediatric patients with short bowel syndrome
por: Marier, Jean‐Francois, et al.
Publicado: (2021)

Gastric Foveolar Hyperplastic Polyps in 2 Children With Short Bowel Syndrome on Long-Term Teduglutide
por: Salazar, Jonathan A., et al.
Publicado: (2023)

Predictive Potential of Biomarkers of Intestinal Barrier Function for Therapeutic Management with Teduglutide in Patients with Short Bowel Syndrome
por: Büttner, Janine, et al.
Publicado: (2023)

Case Report: Morphologic and Functional Characteristics of Intestinal Mucosa in a Child With Short Bowel Syndrome After Treatment With Teduglutide: Evidence in Favor of GLP-2 Analog Safety
por: Falco, Enrico Costantino, et al.
Publicado: (2022)

Teduglutide Promotes Epithelial Tight Junction Pore Function in Murine Short Bowel Syndrome to Alleviate Intestinal Insufficiency
por: Reiner, Johannes, et al.
Publicado: (2020)

Efficacy of Teduglutide for Parenteral Support Reduction in Patients with Short Bowel Syndrome: A Systematic Review and Meta-Analysis
por: Bioletto, Fabio, et al.
Publicado: (2022)

Improvement in metabolic indices including thyroid hormones via enhanced absorption of nutrients by Teduglutide in short bowel syndrome
por: Oba, Ken C., et al.
Publicado: (2022)

Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and/or intravenous fluid requirements in patients with short bowel syndrome
por: Jeppesen, P B, et al.
Publicado: (2011)

Teduglutide in amyloidosis‐associated intestinal failure
por: Luhn, Clara, et al.
Publicado: (2023)

Efficacy of teduglutide in a patient with Crohn’s disease and short bowel syndrome on enteral nutrition: let’s start to think out of the box
por: Barberio, Brigida, et al.
Publicado: (2019)

SAT-LB86 Improvement In Metabolic Indices Including Thyroid HormonesVia Enhanced Absorption Of Nutrients By Teduglutide In Short Bowel Syndrome
por: Oba, Ken C, et al.
Publicado: (2020)

Quality of Life in Teduglutide-Treated Patients with Short Bowel Syndrome Intestinal Failure—A Nested Matched Pair Real-World Study
por: Blüthner, Elisabeth, et al.
Publicado: (2023)

Effects of glepaglutide, a long‐acting glucagon‐like peptide‐2 analog, on intestinal morphology and perfusion in patients with short bowel syndrome: Findings from a randomized phase 2 trial
por: Naimi, Rahim M., et al.
Publicado: (2022)

Apo AIV and Citrulline Plasma Concentrations in Short Bowel Syndrome Patients: The Influence of Short Bowel Anatomy
por: López-Tejero, M. Dolores, et al.
Publicado: (2016)

GLP-2 analog teduglutide significantly reduces need for parenteral nutrition and stool frequency in a real-life setting
por: Schoeler, Marc, et al.
Publicado: (2018)

Newer Vistas in Glucagon-Like Peptide-1 Analog Therapy - Marvels of Peptide Engineering
por: Jacob, Jubbin Jagan, et al.
Publicado: (2021)

Changes in Parenteral Nutrition Requirements and BMI in Patients with Parenteral Nutrition-Dependent Short Bowel Syndrome after Stopping Teduglutide—9 Years of Follow-Up
por: Zaczek, Zuzanna, et al.
Publicado: (2022)

Apraglutide, a novel glucagon‐like peptide‐2 analog, improves fluid absorption in patients with short bowel syndrome intestinal failure: Findings from a placebo‐controlled, randomized phase 2 trial
por: Eliasson, Johanna, et al.
Publicado: (2021)

Bridging intestinal failure with Teduglutide – A case report
por: Schlager, Lukas, et al.
Publicado: (2021)

Glucagon-like peptide-2 analogues for Crohn’s disease patients with short bowel syndrome and intestinal failure
por: Pizzoferrato, Marco, et al.
Publicado: (2022)

Clinical Impact of Glucagon-Like Peptide-1 Receptor Analogs on the Complications of Obesity
por: Yazıcı, Dilek, et al.
Publicado: (2022)

Apraglutide, a novel once‐weekly glucagon‐like peptide‐2 analog, improves intestinal fluid and energy absorption in patients with short bowel syndrome: An open‐label phase 1 and 2 metabolic balance trial
por: Eliasson, Johanna, et al.
Publicado: (2022)

Safety Findings in Pediatric Patients During Long‐Term Treatment With Teduglutide for Short‐Bowel Syndrome–Associated Intestinal Failure: Pooled Analysis of 4 Clinical Studies
por: Hill, Susan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_diimjlbshgs794gq5vv889p9bj